Premium
NEUROPHARMACOLOGY
Author(s) -
Nicholas J. Giarman
Publication year - 1996
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.1996.11.s1.193
Subject(s) - neuropharmacology , citation , psychology , computer science , information retrieval , medicine , neuroscience , world wide web
Bromocriptine, a dopamine (DA) agonist, alleviates symptoms of Parkinson's disease (PD) and is used for the treatment of PD. However, from its introduction to the treatment of PJ?, bromocriptine has been noted to prod~ce better therapeutic effects when used with levodopa. In thts study, we exammed biochemical changes caused by bromocriptine administration with and without levodopa and evaluated the effects of the treatments on DA turnover in the mouse striatum. DA turnover was suppressed by the administration of bromocriptine alone with increase in the DA content, and DA turnover promoted by the administration of levodopa. ~~en the two drugs were administered together, bromocr~phne markedly increased the enhancement of DA turnover m the striatum by levodopa. These findings support the excellent therapeutic effects of the combination of bromo~riptine and levodopa, which have been known from expenence. The results of this study, indicating bromocriptine therapy with the concomitant use of levodopa causes a greater enhancement of the DAergic function, are considered to provide a theoretical basis for this combination therapy. P723 TRF.ATMF.NT OF HALLUCINATIONS WITH ONDANSETRON IN 23 PATIENTS WITH ADVANCED PARKINSON'S DISEASE. LJ L.6pez del Vat• . I Jerlc6 Pascual•, JA L.6pez del Val•• •Neurology Servlce.Unlverslty Clinical Hospital. ••Teaching Unity Primacy Health Care. Zaragoza. Spain.